Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma.
| Autor: | Talley PJ; Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust, Western Bank, Sheffield S10 2TH, UK polly.talley@sch.nhs.uk., Chantry AD; Sheffield Myeloma Research Team (SMaRT), Department of Oncology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK., Buckle CH; Sheffield Myeloma Research Team (SMaRT), Department of Oncology, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | British medical bulletin [Br Med Bull] 2015 Mar; Vol. 113 (1), pp. 15-30. Date of Electronic Publication: 2015 Feb 06. |
| DOI: | 10.1093/bmb/ldu041 |
| Abstrakt: | Background: Despite advances in the treatment of multiple myeloma (MM), it remains an incurable malignant disease. Myeloma genetics is intrinsically complex, but it offers an opportunity to categorize the disease and apply a personalized medicine approach. Areas of Agreement: Research into the genetics of myeloma is moving at a fast pace and is highlighting areas and patient cohorts likely to benefit from specific treatment. Targeting residual disease is likely to be crucial to improved clinical outcome. Areas of Controversy: Patients in clinical trials are more likely to receive genetic diagnosis than non-trial patients, for whom access is ad hoc and dependent upon regional commissioning arrangements. Areas Timely for Developing Research: Relating genetics to potential treatment pathways will become crucial for improved myeloma outcomes. Universal access to standardized genetic testing will facilitate modern personalized treatments. (© The Author 2015. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|